Pusch Wolfgang sold $198K of BRKR

Pusch Wolfgang (President BMID Group) sold 3,473 shares of BRUKER CORP (BRKR) at $56.90 ($0.20M total) on 2026-08-17.

Original reporting
SEC EDGAR · Pusch Wolfgang
Published Aug 18, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 8:46 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BRKR
Neutral
medium confidence
Mentioned
$BRKR
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BRKRNeutralLow
01

Why it matters

The newest fact is the specific open-market sale details by an officer (President, BMID Group) on 2026-08-17, filed on 2026-08-18.

02

Market read

Traders may note insider selling, but the disclosed dollar value is small and there is no accompanying fundamental catalyst.

03

What to watch

The filing does not indicate a 10b5-1 plan, but it also provides no context on motivations or whether other insiders are buying/selling.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-18, transaction dated 2026-08-17

Background

The article is an SEC Form 4 insider transaction disclosure for Bruker Corp (BRKR).

Company-level read

Ticker impact

$BRKRNeutralMedium confidence
Context

Form 4 shows Pusch Wolfgang sold 3,473 BRKR shares in an open-market sale for about $197.6K.

Expected impact

Likely minimal near-term impact; any effect is more about signaling than new fundamentals.

Evidence & confidence

The filing is a disclosed transaction size of roughly $0.2M and lacks any accompanying corporate event, guidance, or operational change.

Market effects

No clear sector read-through from a single small insider sale.

None.

None.

Counterpoint

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs rather than bearish expectations.

Key entities

  • BRUKER CORP

    Subject of the Form 4 insider transaction disclosure.

  • Pusch Wolfgang

    President, BMID Group, reported an open-market sale of BRKR shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BRKRMed

Bruker Scientific Instruments BioSpin BSI Chemicals, Applied Markets, Life Sciences, In Vitro Diagnostics, Detection Bruker Energy & Supercon Technologies…

BRUKER CORP (BRKR) filed an SEC Form 8-K — Other Events. Exhibit 99.1 As Reported As Recast Bruker Scientific Instruments ("BSI") BioSpin BSI Chemicals, Applied Markets, Life Sciences, In Vitro Diagnostics, Detection ("BSI CALID") BSI NANO Bruker Energy & Supercon Technologies ("BEST") Corporate Total BSI Biosystems ("BIOS") BSI Microb

$BRKRHighAI 8/10

Bruker Corp (BRKR) Q3 2026 Earnings Call Highlights: Margin Expansion and Strong

Bruker Corp (BRKR) reported Q3 2026 with 0.7% organic revenue growth, but significant margin expansion, with non-GAAP gross margin up 120 bps to 51.3% and operating margin up 400 bps to 16.3%. Non-GAAP EPS grew 24% year-over-year to $0.56. Bookings trends remained positive, with BSI book-to-bill above 1 for five quarters. However, semiconductor metrology and NMR faced pushouts, and a $175 million goodwill impairment charge was recorded.

$BRKRHighAI 9/10

Why is Bruker stock surging today?

Bruker (BRKR) stock rose 14.2% after reporting Q3 2026 earnings of $0.56 per share, beating estimates by 33%, with revenue at $874M. Non-GAAP operating margin expanded 400 bps to 16.3%. Jefferies raised its price target to $70. Management reconfirmed full-year EPS guidance of $2.10–$2.15. The stock hit a 52-week high of $68.98.

$BRKRMed

Bruker (BRKR) Q3 2026 Earnings Call Transcript

Bruker (BRKR) reported Q3 2026 revenues of $874M, up 1.6% YoY, with non-GAAP EPS of $0.56, up 24%. CEO Frank Laukien highlighted growth in U.S. academic/government, China, and semiconductor metrology markets. The company expects revenue acceleration and margin expansion, driven by strong bookings trends and strategic investments in AI and organ-on-a-chip technologies.

$BRKRMed

Bruker Corporation Q3 2026 Earnings Call Summary

Bruker Corporation reported Q3 2026 earnings with 400 basis points year-over-year non-GAAP operating margin expansion. The BSI segment had a book-to-bill ratio over one for five quarters, and China BSI organic bookings grew over 20%. Management reconfirmed full-year 2026 organic revenue growth of 1% to 2% and non-GAAP EPS of $2.10 to $2.15. They expect double-digit EPS growth and at least 100 basis points of further operating margin expansion for fiscal year 2027.